Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Directly disrupting the Hsp90-Cdc37 complex can selectively down-regulate kinase clients of Hsp90 and achieve cell cycle arrest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, the heat shock protein (Hsp90)-Cdc37 PPI promotes colorectal cancer.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [104]
In the citing paper
“PPI inhibitors of Hsp90-Cdc37 could achieve selective inhibition of Hsp90 kinase without affecting other interactions that could lead to unnecessary toxicity [104].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Lee, T., Duan, Y., Wang, W., et al. (2000) · Accounts of Chemical Research · doi:10.1021/ar000033j · Cited by 4,978
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Targeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
Gohlke, H., Kiel, C., & Case, D. A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00610-7 · Cited by 1,192 · cited 1×
“(35, 36), which might provide critical insights into hotspots.”
BackgroundHsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891
Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition
Taipale, M., Krykbaeva, I., Koeva, M., Kayatekin, C., Westover, K. D., Karras, G. I., & Lindquist, S. (2012) · Cell · doi:10.1016/j.cell.2012.06.047 · Cited by 879 · cited 1×
“Quantitative analysis of Hsp90-cochaperone interactions has been reported to reveal specificity in substrate recognition (6).”
BackgroundConverging free energy estimates: MM‐PB(GB)SA studies on the protein–protein complex Ras–Raf
Gohlke, H., & Case, D. A. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.10379 · Cited by 860 · cited 1×
“(35, 36), which might provide critical insights into hotspots.”
BackgroundCheatham, T. E. I., Miller, J. L., Fox, T., Darden, T. A., & Kollman, P. A. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00119a045 · Cited by 859 · cited 1×
“In the whole simulation process, the particle mesh Ewald method was used to calculate long-range electrostatic interactions (33).”
MethodAll-Atom Structure Prediction and Folding Simulations of a Stable Protein
Simmerling, C., Strockbine, B., & Roitberg, A. E. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0273851 · Cited by 589
The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones
Li, J., Soroka, J., & Buchner, J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.09.003 · Cited by 498 · cited 4×
“Different cochaperones, including Hsp70, Hsp40, Hsp70/Hsp90organizing protein, Cdc37, C terminus of heat shock cognate protein 70 (HSC70)–interacting protein, small glutamine-rich tetratricopeptide repeat (TPR)–containing protein , TPR-containing protein associated with Hsp90 (TAH1), p23, protein phosphatase 5, and ac…”
BackgroundInfluentialAtomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase
Verba, K. A., Wang, R. Y.-R., Arakawa, A., Liu, Y., Shirouzu, M., Yokoyama, S., & Agard, D. A. (2016) · Science · doi:10.1126/science.aaf5023 · Cited by 424 · cited 4×
“The formation of the Hsp90-Cdc37-kinase polycomplex ultimately facilitates kinases integrating into the Hsp90 chaperone machine to result in a mature state (9).”
BackgroundMethodInfluentialA novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
Zhang, T., Hamza, A., Cao, X., Wang, B., Yu, S., Zhan, C.-G., & Sun, D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0484 · Cited by 363 · cited 1×
“Although DCZ3112 and many other natural products (such as celastrol) could inhibit Hsp90-Cdc37 PPI at the cellular level, the accurate binding site and regulation mechanism remained unclear (18, 19).”
BackgroundThe Mechanism of Hsp90 Regulation by the Protein Kinase-Specific Cochaperone p50cdc37
Roe, S. M., Ali, M. M. U., Meyer, P., Vaughan, C. K., Panaretou, B., Piper, P. W., Prodromou, C., & Pearl, L. H. (2004) · Cell · doi:10.1016/s0092-8674(03)01027-4 · Cited by 349 · cited 3×
“The binding interface between Hsp90 and Cdc37 appears to be discrete and dynamic, involving a ~1056-Å2 molecular surface and limited critical interactions to reveal a micromolar binding affinity in vitro (11).”
BackgroundResultTargeting HSP90 for cancer therapy
Mahalingam, D., Swords, R., Carew, J. S., Nawrocki, S. T., Bhalla, K., & Giles, F. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605066 · Cited by 317 · cited 1×
“A remarkable number of Hsp90 client proteins play important roles in the growth and proliferation of cancer cells (2).”
BackgroundStructure of an Hsp90-Cdc37-Cdk4 Complex
Vaughan, C. K., Gohlke, U., Sobott, F., Good, V. M., Ali, M. M. U., Prodromou, C., Robinson, C. V., Saibil, H. R., & Pearl, L. H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.07.016 · Cited by 293
Hong, D. S., Banerji, U., Tavana, B., George, G. C., Aaron, J., & Kurzrock, R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.10.001 · Cited by 259
Hsp90 and Cdc37 – a chaperone cancer conspiracy
Pearl, L. H. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.011 · Cited by 242 · cited 1×
“Among them, cochaperone Cdc37 is responsible for recruiting kinases to Hsp90, and it has been assumed to be a specifically kinase-targeting subunit for the Hsp90 chaperone system (7).”
BackgroundCharacterization of Celastrol to Inhibit Hsp90 and Cdc37 Interaction
Zhang, T., Li, Y., Yu, Y., Zou, P., Jiang, Y., & Sun, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.051532 · Cited by 199 · cited 1×
“Although few studies have revealed possible key residues on the Hsp90-Cdc37 binding interface, an explicit small-molecule binding site to disrupt Hsp90-Cdc37 remains unknown (12, 20, 21).”
BackgroundTargeting the oncogene and kinome chaperone CDC37
Gray, P. J., Prince, T. L., Cheng, J., Stevenson, M. A., & Calderwood, S. K. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2420 · Cited by 136 · cited 2×
“Increased levels of Hsp90-Cdc37 complexes regulate the folding and stabilization of protein kinases required for proliferation or recycle rounds of kinase reactivation (26, 27).”
BackgroundSmith, J. R., Clarke, P. A., de Billy, E., & Workman, P. (2009) · Oncogene · doi:10.1038/onc.2008.380 · Cited by 134 · cited 1×
“(28) reported that the knockdown of Cdc37 in HCT116 cells significantly reduced the phosphorylation of AKT and extracellular signal–regulated kinase 1/2 (ERK1/2) without obvious effects on the protein levels of both AKT and ERK1/2.”
BackgroundDevelopment of a Fluorescence Polarization Assay for the Molecular Chaperone Hsp90
Kim, J., Felts, S. J., Llauger, L., He, H., Huezo, H., Rosen, N. X., & Chiosis, G. (2004) · SLAS DISCOVERY · doi:10.1177/1087057104265995 · Cited by 109 · cited 2×
“Furthermore, we performed an ATPase assay and fluorescence polarization (FP) assay (a classic approach to screening Hsp90 inhibitors targeting the ATP pocket) to determine whether DDO-5936 affects the Hsp90 ATPase function (22).”
MethodGray, P. J., Stevenson, M. A., & Calderwood, S. K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-3162 · Cited by 107 · cited 1×
“Cdc37 exhibits increasing levels in proliferating tissues and is prominently expressed in multiple cancers, while most normal tissues, without malignant proliferation, do not require Cdc37 (15).”
BackgroundMandal, A. K., Lee, P., Chen, J. A., Nillegoda, N., Heller, A., DiStasio, S., Oen, H., Victor, J., Nair, D. M., Brodsky, J. L., et al. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200604106 · Cited by 104
Stepanova, L., Yang, G., DeMayo, F. J., Wheeler, T. M., Finegold, M. J., Thompson, T. C., & Harper, J. W. (2000) · Oncogene · doi:10.1038/sj.onc.1203561 · Cited by 92 · cited 1×
“Hsp90-Cdc37 synergistically acts as a facilitator of oncogenesis to help the correct folding of a wide range of overexpressed or mutated oncogenic proteins, accelerating tumorigenic influence (10).”
BackgroundDehner, A., Furrer, J., Richter, K., Schuster, I., Buchner, J., & Kessler, H. (2003) · ChemBioChem · doi:10.1002/cbic.200300658 · Cited by 75
Huang, W., Ye, M., Zhang, L., Wu, Q.-D., Zhang, M., Xu, J., & Zheng, W. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-150 · Cited by 74
Self-citationDifferential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System
Hallett, S. T., Pastok, M. W., Morgan, R. M. L., Wittner, A., Blundell, K. L. I. M., Felletár, I., Wedge, S. R., Prodromou, C., Noble, M. E. M., Pearl, L. H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.042 · Cited by 67 · cited 1×
“Recently, it has been proposed that binding of CDK4/6 to Cdc37 could be blocked by their ATP competitive inhibitors (29).”
BackgroundA global view of Hsp90 functions
Chiosis, G., Dickey, C. A., & Johnson, J. L. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2481 · Cited by 63 · cited 1×
“INTRODUCTION Heat shock protein 90 (Hsp90) is a well-known adenosine 5′-triphosphate (ATP)–dependent protein chaperone that achieves cellular protein homeostasis (1).”
BackgroundThe Human Cdc37·Hsp90 Complex Studied by Heteronuclear NMR Spectroscopy
Sreeramulu, S., Jonker, H. R. A., Langer, T., Richter, C., Lancaster, C. R. D., & Schwalbe, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806715200 · Cited by 62 · cited 1×
“Although few studies have revealed possible key residues on the Hsp90-Cdc37 binding interface, an explicit small-molecule binding site to disrupt Hsp90-Cdc37 remains unknown (12, 20, 21).”
BackgroundChen, X., Liu, P., Wang, Q., Li, Y., Li, F., Fu, H., Zhu, J., Chen, Z., Zhu, W., Xie, C., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.012 · Cited by 55 · cited 1×
“Although DCZ3112 and many other natural products (such as celastrol) could inhibit Hsp90-Cdc37 PPI at the cellular level, the accurate binding site and regulation mechanism remained unclear (18, 19).”
BackgroundCdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival.
Schwarze, S. R., Fu, V. X., & Jarrard, D. F. (2003) · PubMed · Cited by 48
Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction
Wang, L., Li, L., Zhou, Z., Jiang, Z., You, Q., & Xu, X. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.074 · Cited by 44
Self-citationA Dynamic View of ATP-coupled Functioning Cycle of Hsp90 N-terminal Domain
Zhang, H., Zhou, C., Chen, W., Xu, Y., Shi, Y., Wen, Y., & Zhang, N. (2015) · Scientific Reports · doi:10.1038/srep09542 · Cited by 43
Self-citationNovel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90
Jiang, F., Wang, H., Jin, Y., Zhang, Q., Wang, Z., Jia, J.-M., Liu, F., Wang, L., Bao, Q., Li, D., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00912 · Cited by 40
Self-citationJiang, Y., Bernard, D., Yu, Y., Xie, Y., Zhang, T., Li, Y., Burnett, J., Fu, X., Wang, S., & Sun, D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.103390 · Cited by 38 · cited 2×
“Although few studies have revealed possible key residues on the Hsp90-Cdc37 binding interface, an explicit small-molecule binding site to disrupt Hsp90-Cdc37 remains unknown (12, 20, 21).”
BackgroundApplication of Molecular Dynamics Simulations to Spin-labeled Oligonucleotides
Darian, E., & Gannett, P. M. (2005) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2005.10507028 · Cited by 37
NMR Backbone Assignment of the N-terminal Domain of Human HSP90
Jacobs, D. M., Langer, T., Elshorst, B., Saxena, K., Fiebig, K. M., Vogtherr, M., & Schwalbe, H. (2006) · Journal of Biomolecular NMR · doi:10.1007/s10858-006-9030-0 · Cited by 22
He, J., Niu, X., Hu, C., Zhang, H., Guo, Y., Ge, Y., Wang, G., & Jiang, Y. (2013) · Protein Expression and Purification · doi:10.1016/j.pep.2013.09.007 · Cited by 5 · cited 1×
“Although some mutagenesis studies were performed to explore the important residues in Hsp90-Cdc37, during dynamic processes, the precise recognition interactions and potential small-molecule binding sites remained unclear (12, 13).”
Background
Cited by
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions
Li, L., Wang, L., You, Q.-D., & Xu, X.-L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00940 · Cited by 202
Self-citationRational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions
Wang, X., Ni, D., Liu, Y., & Lu, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.682675 · Cited by 150
“Without doubt, it is an ever challenging task to design small molecules possessing rigid and hydrophobic features by downsizing the molecular size and mimicking key residues of original peptides (Wang et al., 2019).”
BackgroundPAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson’s disease
Park, H., Kam, T., Peng, H., Chou, S.-C., Mehrabani-Tabari, A. A., Song, J., Yin, X., Karuppagounder, S. S., Umanah, G. K. E., Rao, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.020 · Cited by 134
Heat shock protein 90: biological functions, diseases, and therapeutic targets
Wei, H., Zhang, Y., Jia, Y., Chen, X., Niu, T., Chatterjee, A., He, P., & Hou, G. (2024) · MedComm · doi:10.1002/mco2.470 · Cited by 131
“159 Furthermore, Chen et al. 273 conducted a study on another inhibitor known as DCZ3112, which also targets the HSP90–CDC37 PPI.”
BackgroundZuo, W., Pang, Q., Zhu, X., Yang, Q., Zhao, Q., He, G., Han, B., & Huang, W. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01601-1 · Cited by 113
Metadata
- Authors
- Wang, L., Zhang, L., Li, L., Jiang, J., Zheng, Z., Shang, J., Wang, C., Chen, W., Bao, Q., Xu, X., Jiang, Z., Zhang, J., & You, Q.
- Affiliations
- China Pharmaceutical University (CN)
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Jiang, Zhengyu
- Zhang, Jian
- You, Qidong
- ORCID
- Venue
- Science Advances
- Published
- 2019-09-06
- Volume
- 5
- Issue
- 9
- Pages
- eaax2277-eaax2277
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC6750927
- OpenAlex
- W2974325953
- Cited by
- 110
- References
- 39
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 18 · 2023: 10 · 2022: 17 · 2021: 16 · 2020: 14 · 2019: 1
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81573346, 81773639, 81773581, 81602948)
- China Postdoctoral Science Foundation (2018M642376)
- Double First Class Innovation Team of China Pharmaceutical University (CPU2018GY02)
- Natural Science Foundation of Jiangsu Province of China (BK2016746)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- protein-protein interaction, small molecule inhibitors, colorectal cancer, CDK4, cell cycle arrest, HCT116 cells, Hsp90 chaperone, cancer therapy
- MeSH terms
- A549 Cells, PC-3 Cells, Animals, Antineoplastic Agents, Humans, Mice, Inbred BALB C, Mice, Nude, Neoplasm Proteins, Colorectal Neoplasms, Cell Cycle Proteins, Chaperonins, HSP90 Heat-Shock Proteins, HT29 Cells, Xenograft Model Antitumor Assays, HCT116 Cells, Mice, Hep G2 Cells, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.